Zymeworks Inc.: insider trading
112 trades by 14 directors, officers and 10% owners since 2022, from their SEC Form 4 and 5 filings.
Bought, 12 months
$0
0 purchases by 0 insiders
Sold, 12 months
$6.4 M
15 sales by 6 insiders
Bought, 3 months
$0
0 purchases
Sold, 3 months
$1.8 M
5 sales
Insider buying and selling by month
Open-market purchases and sales by value, last three years.
Insiders (14)
Each insider's latest direct holding and their open-market trades of the last 12 months, most recent first.
| Insider | Shares owned directly | Bought, 12 m | Sold, 12 m | Latest trade |
|---|---|---|---|---|
| Scott PlatshonEVP, Chief Business Officer | 21,745 | — | $382 K | |
| Paul Andrew MooreChief Scientific Officer | 33,756 | — | $1.8 M | |
| Adam SchayowitzEVP, Head of R&D | 23,205 | — | $358 K | |
| Mark HollywoodEVP & Chief Operating Officer | 133,852 | — | $139 K | |
| Jeffrey T. L. SmithEVP & Chief Medical Officer | 26,708 | — | $476 K | |
| Kenneth GalbraithChair & CEO, Director | 226,842 | — | $3.3 M | |
| Leone D. PattersonEVP, Chief Bus & Fin Officer | 459 | — | — | |
| Gregory Austin CiongoliDirector | 488,500 | — | — | |
| Oleg NodelmanDirector, 10% owner | — | — | — | |
| EcoR1 Capital, LLCDirector, 10% owner | — | — | — | |
| Christopher AstleSVP & Chief Financial Officer | 6,503 | — | — | |
| Neil A. KlompasPresident & COO | 17,032 | — | — | |
| Neil JosephsonChief Medical Officer | 14,449 | — | — | |
| Redmile Group, LLC10% owner | — | — | — |
Trades#
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Scott PlatshonEVP, Chief Business Officer | Sell | -15,292 | $24.95 | $382 K | 21,745 | Form 4 |
| filed | Paul Andrew MooreChief Scientific Officer | Sell | -7,367 | $26.14 | $193 K | 66,130 | Form 4 |
| filed | Paul Andrew MooreChief Scientific Officer | Sell | -7,374 | $26.09 | $192 K | 58,756 | Form 4 |
| filed | Paul Andrew MooreChief Scientific Officer | Sell | -25,000 | $26.04 | $651 K | 33,756 | Form 4 |
| filed | Adam SchayowitzEVP, Head of R&D | Sell | -13,832 | $25.85 | $358 K | 23,205 | Form 4 |
| filed | Mark HollywoodEVP & Chief Operating Officer | Sell | -6,120 | $22.67 | $139 K | 132,913 | Form 4 |
| filed | Kenneth GalbraithChair & CEO, Director | Sell | -30,424 | $22.67 | $690 K | 226,842 | Form 4 |
| filed | Paul Andrew MooreChief Scientific Officer | Sell | -9,560 | $22.67 | $217 K | 48,497 | Form 4 |
| filed | Jeffrey T. L. SmithEVP & Chief Medical Officer | Sell | -9,310 | $22.67 | $211 K | 26,708 | Form 4 |
| filed | Kenneth GalbraithChair & CEO, Director | Sell | -22,657 | $25.10 | $569 K | 158,286 | Form 4 |
| filed | Paul Andrew MooreChief Scientific Officer | Sell | -9,289 | $25.10 | $233 K | 31,212 | Form 4 |
| filed | Jeffrey T. L. SmithEVP & Chief Medical Officer | Sell | -10,538 | $25.10 | $265 K | 18,352 | Form 4 |
| filed | Kenneth GalbraithChair & CEO, Director | Sell | -31,686 | $25.10 | $795 K | 193,266 | Form 4 |
| filed | Paul Andrew MooreChief Scientific Officer | Sell | -10,821 | $25.10 | $272 K | 40,391 | Form 4 |
| filed | Kenneth GalbraithChair & CEO, Director | Sell | -47,528 | $27.02 | $1.3 M | 133,275 | Form 4 |
| filed | Paul Andrew MooreChief Scientific Officer | Sell | -9,792 | $14.92 | $146 K | 14,741 | Form 4 |
| filed | Jeffrey T. L. SmithEVP & Chief Medical Officer | Sell | -11,110 | $14.92 | $166 K | 8,890 | Form 4 |
| filed | Kenneth GalbraithChair & CEO, Director | Sell | -23,885 | $14.92 | $356 K | 47,543 | Form 4 |
| filed | Kenneth GalbraithChair & CEO, Director | Sell | -33,406 | $14.92 | $498 K | 80,803 | Form 4 |
| filed | Paul Andrew MooreChief Scientific Officer | Sell | -11,408 | $14.92 | $170 K | 23,333 | Form 4 |
| filed | Paul Andrew MooreChief Scientific Officer | Sell | -2,339 | $11.22 | $26 K | 7,367 | Form 4 |
| filed | Christopher AstleSVP & Chief Financial Officer | Sell | -1,431 | $11.22 | $16 K | 6,503 | Form 4 |
| filed | Kenneth GalbraithChair & CEO, Director | Sell | -5,706 | $11.22 | $64 K | 23,762 | Form 4 |
| filed | Kenneth GalbraithChair & CEO, Director | Sell | -18,198 | $10.65 | $194 K | 29,468 | Form 4 |
| filed | Paul Andrew MooreChief Scientific Officer | Sell | -7,460 | $10.65 | $79 K | 9,706 | Form 4 |
| filed | Christopher AstleSVP & Chief Financial Officer | Sell | -4,563 | $10.65 | $49 K | 7,934 | Form 4 |
| filed | Christopher AstleSVP & Chief Financial Officer | Sell | -886 | $9.130 | $8 K | 1,997 | Form 4 |
| filed | Neil A. KlompasPresident & COO | Sell | -2,977 | $7.830 | $23 K | 17,032 | Form 4 |
| filed | Christopher AstleSVP & Chief Financial Officer | Sell10b5-1 plan · amended | -887 | $6.010 | $5 K | 1,333 | Form 4/A |
| filed | Christopher AstleSVP & Chief Financial Officer | Sell10b5-1 plan | -887 | $6.010 | $5 K | 1,333 | Form 4 |
| filed | Neil JosephsonChief Medical Officer | Sell10b5-1 plan · amended | -2,475 | $8.100 | $20 K | 14,449 | Form 4/A |
| filed | Neil JosephsonChief Medical Officer | Sell10b5-1 plan | -2,475 | $8.100 | $20 K | 14,449 | Form 4 |
Source: SEC Forms 4 and 5. A trade under a 10b5-1 plan was scheduled in advance. For information only; not investment advice